obesity drug news today october 21 2025 glp-1 trends 2025: real-world data, patient outcomes & future therapies obesity drug news today october

Pharmacotherapy of weight-loss and obesity with a focus on GLP 1-receptor agonists

Dosing regimens vary between short-acting and long-acting formulations

While current therapies are often effective during initiation, they tend to lose efficacy as time passes and only provide symptom control without addressing the underlying progressive nature of the disease

Mullard A

Compounded semaglutide has emerged as a lower-cost alternative, with prices ranging from $150 to $500 per month depending on the pharmacy and dosage

The Science Behind Dual Agonist Design Creating tirzepatide required sophisticated pharmaceutical engineering to activate both receptors effectively